Abstract:Abstract Introduction A hypermetabolic state develops after severe burn injury altering volume distribution, creatinine clearance (CrCl), and hepatic metabolism. This ultimately impacts pharmacokinetics of drugs, including enoxaparin, the standard prophylactic venous thromboembolism (VTE) anticoagulant. Understanding specific factors in burn patients that impact the pharmacokinetics of enoxaparin is necessary to reduce rates of VTE. This study aims to identify risk factors associated with subtherapeutic levels of enoxaparin, measured by peak anti-Xa levels, in burn patients. Methods Patients admitted to a regional burn center over a six-month period were included in this retrospective review. Patients on enoxaparin 40mg twice a day (BID) for VTE prophylaxis and had a peak anti-Xa level were included. Exclusion criteria included polytrauma, therapeutic anticoagulation or anti-platelet therapy, a history of chronic kidney disease, cirrhosis, coagulation disorder, heparin induced thrombocytopenia (HIT), or thrombocytopenia at admission. Patient demographics, burn injury characteristics, and lab values for peak anti-Xa levels and admission CrCl were obtained. For prophylactic enoxaparin, a therapeutic level is 0.2-0.4U/mL and a subtherapeutic level is < 0.2U/mL. Patients were separated into groups based on therapeutic or subtherapeutic levels. Differences between groups were evaluated using two-sample t-test or Wilcoxon rank-sum test. Results Both the subtherapeutic and therapeutic groups had 13 patients. No patient developed a symptomatic VTE within 31 days of discharge. There were no significant differences in gender, BMI (30.4 vs 31.6 kg/m2), presence of inhalation injury, or ICU length of stay (5 vs 3 days) between groups. Patients in the subtherapeutic group were significantly younger (38 vs 48 years), with a higher TBSA (22.6% vs 6%), and a higher CrCl at admission (134.2 vs 104.8 mg/dL). In the subtherapeutic group, the highest dose needed to reach a therapeutic level of enoxaparin was 60mg BID and the median final dose was 50mg BID. Conclusions A delay in initiation of VTE prophylaxis is associated with increased rates of VTE in burn patients, and a delay to therapeutic levels of VTE prophylaxis will likely lead to increased rates of VTE as well. Factors associated with a delay to therapeutic enoxaparin levels were age, %TBSA, and CrCl. A uniform standard dose of enoxaparin may not be effective for all burn patients. Applicability of Research to Practice Burn patients are a unique subgroup that require special consideration in every aspect of care, including VTE prophylaxis. Risk factors associated with subtherapeutic enoxaparin levels after burn injury need to be identified to guide the development of effective VTE prophylaxis guidelines.

Enoxaparin treatment dosing for venous thromboembolism in pediatric patients with obesity

Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients

Evaluation of Anti-Xa Target Attainment with Prophylactic Enoxaparin Dosing Regimens for Venous Thromboembolism Prophylaxis in Morbidly Obese Patients

A systematic review of therapeutic enoxaparin dosing in obesity

Therapeutic Enoxaparin Dosing in Obesity

Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population

Comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial

Finding individualised treatment in obese needing enoxaparin (FIT ONE): a multicentre study of therapeutic enoxaparin and the role of anti-factor Xa monitoring

Evaluation of Initial Enoxaparin Dosing and Antifactor Xa Levels in Infants Admitted to the Neonatal Intensive Care Unit

Weight-based enoxaparin thromboprophylaxis in young trauma patients: analysis of the CLOTT-1 registry

One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis

Pharmacokinetic model‐guided enoxaparin dosing in the Neonatal ICU: Retrospective cohort study to plan for prospective feasibility trial

Treatment of Atrial Fibrillation and Venous Thromboembolism with Factor Xa Inhibitors in Severely Obese Patients

Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism

Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial

Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients

Managing venous thrombosis in a pediatric patient with short bowel and congenital nephrotic syndromes: a case report emphasizing rivaroxaban level monitoring

583 Risk Factors Associated with Subtherapeutic Enoxaparin Levels in Burn Patients

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study

Heparin Dosing Regimen Optimization in Veno-Arterial Extracorporeal Membrane Oxygenation: A Pharmacokinetic Analysis

Is the current therapeutic dosage of nadroparin adequate for neonates and infants under 8 months with thromboembolic disease? a population pharmacokinetic study from a national children's medical center